Alexion to build new HQ in Boston, expand R&D in New Haven

Courtesy photo AstraZeneca CEO Pascal Soriot

Write a Comment

By Liese Klein, New Haven Biz

Even as it continues to expand in New Haven, AstraZeneca on Friday announced plans to open a new headquarters for its Alexion Rare Disease group and a strategic R&D center in the Boston area.

More than 1,500 employees of the combined companies will be housed in the new building, to be located in Cambridge’s Kendall Square biotech hub.

Alexion’s R&D “center of excellence” will stay in New Haven, AstraZeneca said in a statement on Friday, and the company is still planning to double Alexion’s lab floor space in the city by the end of 2023. The company currently has 500 workers at its 100 College St. location and is recruiting for 50 more.

Alexion announced earlier this month that it planned to expand into the new bioscience tower currently under construction at 101 College St.

AstraZeneca, which completed its acquisition of New Haven-founded Alexion in July 2021, currently occupies more than 570,000 square feet of R&D and commercial space in the Boston area. The new Alexion HQ is scheduled to be ready for occupancy by 2026.

AstraZeneca CEO Pascal Soriot said, “Our combined company has already successfully leveraged internal scientific synergies, and this move will act as a catalyst for even more external collaboration and innovation.”